NEW YORK (GenomeWeb) – Trovagene reported after the close of the market Monday that its second quarter net loss increased nearly 10-fold year over year due primarily to increased operating expenses and changes in the fair market value of derivatives.

For the three months ended June 30, the San Diego-based molecular diagnostics firm took a net loss of $10.2 million, or $.41 per share, compared to a loss of $1.1 million, or $.17 per share, in Q2 2014. On average, analysts had expected a net loss of $.24 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.